about
Matricellular proteins: a sticky affair with cancersHyaluronan synthase 2 (HAS2) promotes breast cancer cell invasion by suppression of tissue metalloproteinase inhibitor 1 (TIMP-1)Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast CancerUtilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy DeliveryPrognostic value of CD44 expression in renal cell carcinoma: a systematic review and meta-analysisOvarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approachCD44 Acts as a Signaling Platform Controlling Tumor Progression and MetastasisHyaluronan, Inflammation, and Breast Cancer ProgressionSignificance of CD44 expression in head and neck cancer: a systemic review and meta-analysisIduronic acid in chondroitin/dermatan sulfate affects directional migration of aortic smooth muscle cellsHedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancerCancer metastases: challenges and opportunitiesTissue stiffness dictates development, homeostasis, and disease progression.Notch inhibition as a promising new approach to cancer therapy.CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.Cellular heterogeneity profiling by hyaluronan probes reveals an invasive but slow-growing breast tumor subset.Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas.CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markersBMP2 promotes migration and invasion of breast cancer cells via cytoskeletal reorganization and adhesion decrease: an AFM investigation.Extracellular matrix degradation and remodeling in development and diseaseSelf-assembled polymeric micelles based on hyaluronic acid-g-poly(D,L-lactide-co-glycolide) copolymer for tumor targeting.Spatio-temporal patterns of pancreatic cancer cells expressing CD44 isoforms on supported membranes displaying hyaluronic acid oligomers arrays.Cell specific CD44 expression in breast cancer requires the interaction of AP-1 and NFκB with a novel cis-element.Phenotypic heterogeneity of breast cancer stem cells.The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway.Internalization of Met requires the co-receptor CD44v6 and its link to ERM proteins.Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44.Anoikis mediators in oral squamous cell carcinoma.Podosomes in adhesion, migration, mechanosensing and matrix remodeling.Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosomeIn vitro selection of modified RNA aptamers against CD44 cancer stem cell markerCancer stem cells and side population cells in breast cancer and metastasis.Cell-surface receptor for complement component C1q (gC1qR) is a key regulator for lamellipodia formation and cancer metastasis.Lung-residing metastatic and dormant neuroblastoma cells.The Expression and Prognostic Impact of CD95 Death Receptor and CD20, CD34 and CD44 Differentiation Markers in Pediatric Acute Lymphoblastic LeukemiaClinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis.c-Met recruits ICAM-1 as a coreceptor to compensate for the loss of CD44 in Cd44 null mice.
P2860
Q21296660-3AD32962-97C3-4053-88BE-0918E2E77413Q24294210-47B04BC1-51EB-4A1D-8A26-D3DCD2CC91EDQ26773907-2F3FF52B-BE2C-4BAA-9279-E884E7321564Q26786070-96B2DF6C-28D2-433A-9D60-005B6463BA58Q26796554-457F398B-1306-45EA-B9E0-FAFBF32AE5A2Q26826899-19581656-6270-4A47-9FE5-2A4D2CC5C510Q26849477-6EC4C8F4-4FE8-4174-AA45-C78573BE18B0Q26851466-4E7658FD-9F07-4EE1-AE0A-33085F4A886CQ27006607-A55FD153-E661-47C8-9417-7DF30360C96EQ27023399-883812A0-40CA-4F7F-9A15-E99B7F202F9DQ27313839-1779FD66-CA25-4206-A310-618593D3370CQ27322930-B5B4DE4A-4EC5-457E-A12F-A75045BDDB4BQ28088755-CDFDF046-B72D-4E83-8B6E-FD95E7FBA02DQ30400463-20915DDB-1F04-467A-88C7-60DB99123A0BQ30426785-56903C10-BE4C-4E98-AE74-C0F369B3A5A0Q33556551-EF350D33-F7F8-43AE-881C-B64281DFFA63Q33674704-528F8505-1AE9-450B-BC68-101A57175854Q33850064-A852AEDC-406D-44A2-9284-FCF326026DBFQ33922745-55FE5EBB-42F7-4EA7-A5D8-882D8773B3F1Q34034939-68B26161-4051-4927-873A-45F1C3460C8CQ34136497-8D8A9644-22C8-4FAC-B45F-D1F33281AC59Q34216389-BFE8C578-231F-4A71-AE17-9864FE520F2CQ34358519-30E3F0A5-1121-419E-98A5-DB7A8407F3FDQ34391180-A368DE9F-909E-4B58-9C16-978C3C09F94EQ34506057-70C27B85-CEC6-4528-8B03-1A7FB33285B1Q34521202-E6DA2D16-88BF-4E88-BEAB-36B400487F51Q34606294-5865A55F-EB4A-4202-AD2F-AE12015B753EQ34693039-333937DF-96CC-47B7-ABA4-EBE538FF7E1CQ34719626-350B48F7-120C-4508-849E-188C49EB9B86Q34770470-10BBFA7F-52CA-403A-98A0-DDD4E5A89C73Q34785129-A11ED72B-CA7B-41A7-AA4A-F8EBB6F483CEQ34874835-2707161B-B9F3-4890-A8D3-09A436D2F40BQ35023463-8CF8AA3B-C062-4391-B22A-126BD1D815D7Q35028671-688DAA44-C0AC-4C2A-BD2A-8B8E1FAD090AQ35038054-8EDE6850-92E1-494B-8F40-F58482EAD289Q35067763-5391C7D4-08C2-4024-96D1-A815881ECD85Q35070130-DB8EB06A-E1B6-45F9-9C3F-128A5C66217AQ35118521-42776DD1-E966-45CD-A1B0-E97540D8E17EQ35132045-082FBB12-35B8-4C69-84F0-8C438AAED5C6Q35133627-C60E39DB-AB4F-4E94-9326-513DBEE8B892
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
gotara zanistî
@ku-latn
scientific article published on 19 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
name
CD44, a therapeutic target for metastasising tumours.
@en
CD44, a therapeutic target for metastasising tumours.
@nl
type
label
CD44, a therapeutic target for metastasising tumours.
@en
CD44, a therapeutic target for metastasising tumours.
@nl
prefLabel
CD44, a therapeutic target for metastasising tumours.
@en
CD44, a therapeutic target for metastasising tumours.
@nl
P1476
CD44, a therapeutic target for metastasising tumours.
@en
P2093
Véronique Orian-Rousseau
P304
P356
10.1016/J.EJCA.2010.02.024
P577
2010-03-19T00:00:00Z